Advertisement

Uremic Toxins pp 227-237 | Cite as

Kinetics of Solute Removal in Hemodialysis

  • Frank A. Gotch
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 223)

Abstract

The basic premise of dialysis therapy for uremia is that uremic pathophysiology is dependent on abnormal solute levels in body water which can be normalized by dialysis. Consequently, the clinician is concerned with predicting changes in concentration and body content of solutes as a function of the amount of dialysis prescribed. This can best be achieved through kinetic analysis.

Keywords

Carpal Tunnel Syndrome Dialysis Therapy Adequate Dialysis Dialyzer Clearance Middle Molecule 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    A. V. Wolf, D. G. Remp, J. E. Kiley, and G. D. Currie, Artificial kidney function: Kinetics of hemodialysis, J Clin Invest 30:1062–1070 (1951).PubMedCrossRefGoogle Scholar
  2. 2.
    B. H. Scribner, Discussion, Trans Amer Soc Artif Intern Organs 11:29 (1965).Google Scholar
  3. 3.
    A. L. Babb, R. P. Popovitch, T. G. Christopher, and B. H. Scribner, The genesis of the square-meter hour hypotehsis, Trans Amer Soc Artif Intern Organs 17:81–91 (1971).Google Scholar
  4. 4.
    A. L. Babb, P. C. Farrell, D. A. Uvelli, and B. H. Scribner, Hemodialyzer evaluation by examination of solute molecular spectra. Trans Amer Soc Artif Intern Organs 18:98–106 (1972).CrossRefGoogle Scholar
  5. 5.
    A. L. Babb, P. C. Farrell, M. J. Strand, D. A. Uvelli, J. Multinovic, and B. H. Scribner, Residual renal function and chronic hemodialysis therapy, Proc Clin Dialysis & Transplant Forum 2:142–149 (1972).Google Scholar
  6. 6.
    A. L. Babb, M. J. Strand, J. Multinovic, and B. H. Scribner, Quantitative description of dialysis treatment: A dialysis index, Kid Int 7:S23–S30 (1975).Google Scholar
  7. 7.
    A. L. Babb, M. J. Strand, D. A. Uvelli, and B. H. Scribner, The dialysis index: A practical guide to dialysis treatment. Dialysis & Transplantation 6:9–13 (1977).Google Scholar
  8. 8.
    C. M. Kjellstrand, R. L. Evans, R. J. Petersen, L. W. Rust, J. Shideman, T. J. Buselmeier, and L. T. Rozelle, Consideration of the middle molecule hypothesis, Proc Clin Dialysis & Transplant Forum 2:127–142 (1972).Google Scholar
  9. 9.
    F. A. Gotch, J. A. Sargent, and J. H. Peters, Studies on the molecularetiology of uremia, Kid Int 7:S276–280 (1975).Google Scholar
  10. 10.
    M. F. Borah, P. Y. Schoenfeld, F. A. Gotch, J. A. Sargent, M. Wolfson, and M. H. Humphreys, Nitrogen balance during intermittent dialysis therapy of uremia. Kidney Int 14:491–500 (1978).PubMedCrossRefGoogle Scholar
  11. 11.
    F. A. Gotch, J. A. Sargent, M. L. Keen, M. Seid, and R. Foster, Comparative treatment time with Kiil, Gambro and Cordis-Dow kidneys, Proc Clin Dialysis & Transplant Forum 3:217–229 (1973).Google Scholar
  12. 12.
    J. A. Sargent, and F. A. Gotch, Principles and biophysics of dialysis, in; "Replacement of Renal Function by Dialysis", W. Drukker, F. Parsons, J. Maher, eds.. The Hague: Martinus Nijhoff, 2nd edition, 53–96 (1983).CrossRefGoogle Scholar
  13. 13.
    P. C. Farrell, and F. A. Gotch, Dialysis therapy guided by kinetic modeling: Application of a variable-volume single-pool model of urea kinetics. Trans Second Australian Conference on heat and mass transfer, 29–37 (1977).Google Scholar
  14. 14.
    F. A. Gotch, J. A. Sargent, and M. Keen, Clinical results of intermittent dialysis therapy guided by ongoing kinetic analysis of urea metabolism. Trans Amer Soc Artif Intern Organs 22:175–189 (1976).Google Scholar
  15. 15.
    F. A. Gotch, A quantitative evaluation of small and middle molecule toxicity in therapy of uremia. Dialysis & Transplantation 9:183–192 (1980).Google Scholar
  16. 16.
    F. A. Gotch, and J. A. Sargent, A mechanistic analysis of the National Cooperative Dialysis Study (NCDS), Kidney Int 28:526–534 (1985).PubMedCrossRefGoogle Scholar
  17. 17.
    N. M. Laird, C. S. Berkey, and E. G. Lowrie, Modeling success or failure of dialysis therapy: The National Cooperative Dialysis Study, Kidney Int 23:S101-S107 (1983).Google Scholar
  18. 18.
    J. I. Shapiro, W. P. Argy, T. A. Rakowski, A. Chester, A. S. Siemsen, and G. E. Schreiner, The unsuitability of BUN as a criterion for prescription dialysis. Trans Amer Soc Artif Intern Organs 29:129–135 (1983).Google Scholar
  19. 19.
    F. A. Gotch, Discussion, Trans Amer Soc Artif Intern Organs 29:133–134 (1983).Google Scholar
  20. 20.
    F. A. Gotch, Dialysis of the future. Kidney Int (in press).Google Scholar
  21. 21.
    F. Gejyo, S. Odani, T. Yamada, N. Honma, H. Saito, Y. Suzuki, Y Nakagawa, H. Kobayashi, Y. Maruyama, Y. Hirasawa, M. Suzuki, and M. Arakawa, Beta-2 microglobulin: A new form of amyloid protein associated with chronic hemodialysis. Kidney Int 30:385–390 (1986).PubMedCrossRefGoogle Scholar
  22. 22.
    A. Z. Genves, M. Emmett, M. G. White, G. Greenway, and D. B. Michaels, Carpal tunnel syndrome with cystic bone lesions secondary to amyloidosis in chronic hemodialysis patients, Amer Jour Kidney Dis 7:130–134 (1986).Google Scholar
  23. 23.
    C. Vincent, N. Pozet, and J. P. Revillard, Plasma Beta-2 microglobulin turnover in renal insufficiency. Acta Clinica Belgica 35:S10 2–13 (1980).Google Scholar
  24. 24.
    E. M. Landis, and J. R. Pappenheimer, Section II, Circulation, in; "Handbook of Physiology", American Physiology Society, 2:1008Google Scholar
  25. 25.
    J. Bommer, H. P. Seelig, R. Seelig, and E. Ritz, Beta-2 microglobulin levels in hemodialyzed patients. Abstract, EDTA (1986).Google Scholar
  26. 26.
    J. M. Vandenbroucke, C. van Ypersele de Strihou, Relationship between membrane characteristics and dialysis induced changes in Beta-2 microglobulin levels. Abstract, EDTA (1986).Google Scholar

Copyright information

© Plenum Press, New York 1987

Authors and Affiliations

  • Frank A. Gotch
    • 1
  1. 1.Hemodialysis Treatment and Research CenterFranklin HospitalSan FranciscoUSA

Personalised recommendations